Henrik Wulff, Novo Nordisk EVP of product supply, quality and IT (Credit: Novo Nordisk)
Novo unlikely to outsource API production for GLP-1s but will stay engaged with fill-finish partners
Novo Nordisk spelled out how it will try to catch up with the extraordinary demand for its GLP-1 drugs, underscoring its rationale for its in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
